News

Press Release | Feb 06, 2020

Centurion Service Group, a leader in medical equipment solutions, announced today that it has acquired Salt Lake City, UT Monet Medical, an advanced refurbisher of best-in-class beds, stretchers, infusion pumps and other medical equipment with strong ties to major national medical distributors. Originally a medical equipment auction house, Centurion Service Group has firmly cemented its

Press Release | Jan 23, 2020

Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced the pricing of an underwritten public offering of 1,625,000 shares of its common stock at a price to the public of $18.50 per share. The gross proceeds from this

Press Release | Jan 21, 2020

Greenbrook TMS NeuroHealth Centers, one of the leading providers of Transcranial Magnetic Stimulation (TMS) therapy in the United States, announced today that it is now offering BrainsWay’s Deep TMS therapy for patients with obsessive-compulsive disorder (OCD) at its Greenbrook – Cary facility in North Carolina.

Press Release | Jan 21, 2020

Onkos Surgical, Inc. a leader in the field of musculoskeletal oncology and personalized orthopaedics announced today a multi-year agreement with Integrum AB (INTEG B: Nasdaq First North exchange). The collaboration between companies will commence immediately and will be focused on expanding the US market for Integrum’s OPRA™ (Osseoanchored Prostheses for the Rehabilitation of Amputees) Implant

Press Release | Jan 16, 2020

Greenbrook TMS NeuroHealth Centers, one of the leading providers of mental health services in the United States, is now offering BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for patients with obsessive-compulsive disorder (OCD) at their Newport News location in Virginia. Other Greenbrook locations in the state, including Tysons Corner and Glen Allen, have also

Press Release | Jan 13, 2020

Interpace Biosciences, Inc. (Nasdaq: IDXG) (“Interpace” or the “Company”), a leader in leveraging molecular diagnostics and other platforms for the benefit of patients and supporting pharmaceutical development, today announced that it has entered into an agreement for a new Series B Preferred Stock investment of $20 million, consisting of $19 million from 1315 Capital and

Pages 1 2 3 4 5 6 14